Question 1

Do analysts recommend PFE or TEVA?

Accepted Answer

Pfizer presently has a consensus target price of $28.28, indicating a potential downside of 0.10%. Teva Pharmaceutical Industries has a consensus target price of $42.22, indicating a potential upside of 13.49%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Pfizer. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 2 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.19 Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90

Question 2

Is PFE or TEVA a better dividend stock?

Accepted Answer

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.1%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 2.7%. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Teva Pharmaceutical Industries pays out 168.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Question 3

Which has preferable valuation and earnings, PFE or TEVA?

Accepted Answer

Pfizer has higher revenue and earnings than Teva Pharmaceutical Industries. Pfizer is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.58 $7.77B $0.76 37.24 Teva Pharmaceutical Industries $17.31B 2.50 $1.41B $0.60 62.01

Question 4

Do institutionals and insiders hold more shares of PFE or TEVA?

Accepted Answer

68.4% of Pfizer shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Question 5

Is PFE or TEVA more profitable?

Accepted Answer

Pfizer has a net margin of 6.80% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.80% 19.63% 8.46% Teva Pharmaceutical Industries 4.08% 32.64% 6.34%

Question 6

Which has more risk and volatility, PFE or TEVA?

Accepted Answer

Pfizer has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Question 7

Does the media prefer PFE or TEVA?

Accepted Answer

In the previous week, Pfizer had 83 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 91 mentions for Pfizer and 8 mentions for Teva Pharmaceutical Industries. Pfizer's average media sentiment score of 0.98 beat Teva Pharmaceutical Industries' score of 0.65 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 57 Very Positive mention(s) 11 Positive mention(s) 14 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Positive Teva Pharmaceutical Industries 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Question 8

Do analysts rate TEVA or BMY?

Accepted Answer

Teva Pharmaceutical Industries presently has a consensus price target of $42.22, suggesting a potential upside of 13.49%. Bristol Myers Squibb has a consensus price target of $66.06, suggesting a potential downside of 1.98%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Bristol Myers Squibb. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Bristol Myers Squibb 1 Sell rating(s) 10 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.56

Question 9

Is TEVA or BMY a better dividend stock?

Accepted Answer

Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 2.7%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.7%. Teva Pharmaceutical Industries pays out 168.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Question 10

Which has better earnings & valuation, TEVA or BMY?

Accepted Answer

Bristol Myers Squibb has higher revenue and earnings than Teva Pharmaceutical Industries. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teva Pharmaceutical Industries $17.31B 2.50 $1.41B $0.60 62.01 Bristol Myers Squibb $48.19B 2.86 $7.05B $4.54 14.84

Question 11

Do insiders & institutionals believe in TEVA or BMY?

Accepted Answer

54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Question 12

Is TEVA or BMY more profitable?

Accepted Answer

Bristol Myers Squibb has a net margin of 18.87% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Bristol Myers Squibb's return on equity of 66.90% beat Teva Pharmaceutical Industries' return on equity. Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries 4.08% 32.64% 6.34% Bristol Myers Squibb 18.87% 66.90% 14.74%

Question 13

Which has more volatility & risk, TEVA or BMY?

Accepted Answer

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Question 14

Does the media prefer TEVA or BMY?

Accepted Answer

In the previous week, Bristol Myers Squibb had 65 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 73 mentions for Bristol Myers Squibb and 8 mentions for Teva Pharmaceutical Industries. Bristol Myers Squibb's average media sentiment score of 1.45 beat Teva Pharmaceutical Industries' score of 0.65 indicating that Bristol Myers Squibb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 66 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Question 15

Do analysts rate TEVA or SNY?

Accepted Answer

Teva Pharmaceutical Industries currently has a consensus target price of $42.22, indicating a potential upside of 13.49%. Sanofi has a consensus target price of $49.50, indicating a potential upside of 8.82%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Sanofi. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Sanofi 1 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.40

Question 16

Is TEVA or SNY a better dividend stock?

Accepted Answer

Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 2.7%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.9%. Teva Pharmaceutical Industries pays out 168.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Question 17

Which has preferable earnings and valuation, TEVA or SNY?

Accepted Answer

Sanofi has higher revenue and earnings than Teva Pharmaceutical Industries. Sanofi is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teva Pharmaceutical Industries $17.31B 2.50 $1.41B $0.60 62.01 Sanofi $49.35B 2.23 $8.84B $1.91 23.82

Question 18

Do insiders and institutionals believe in TEVA or SNY?

Accepted Answer

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Question 19

Is TEVA or SNY more profitable?

Accepted Answer

Sanofi has a net margin of 8.66% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries 4.08% 32.64% 6.34% Sanofi 8.66% 14.19% 7.95%

Question 20

Which has more volatility & risk, TEVA or SNY?

Accepted Answer

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Question 21

Does the media favor TEVA or SNY?

Accepted Answer

In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Sanofi. MarketBeat recorded 8 mentions for Teva Pharmaceutical Industries and 1 mentions for Sanofi. Sanofi's average media sentiment score of 1.45 beat Teva Pharmaceutical Industries' score of 0.65 indicating that Sanofi is being referred to more favorably in the news media. Company Overall Sentiment Teva Pharmaceutical Industries Positive Sanofi Positive

Question 22

Do analysts recommend TEVA or GSK?

Accepted Answer

Teva Pharmaceutical Industries currently has a consensus target price of $42.22, indicating a potential upside of 13.49%. GSK has a consensus target price of $53.00, indicating a potential upside of 2.60%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, research analysts clearly believe Teva Pharmaceutical Industries is more favorable than GSK. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 GSK 2 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.10

Question 23

Is TEVA or GSK a better dividend stock?

Accepted Answer

Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 2.7%. GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.4%. Teva Pharmaceutical Industries pays out 168.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 55.6% of its earnings in the form of a dividend. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Question 24

Which has better earnings & valuation, TEVA or GSK?

Accepted Answer

GSK has higher revenue and earnings than Teva Pharmaceutical Industries. GSK is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teva Pharmaceutical Industries $17.31B 2.50 $1.41B $0.60 62.01 GSK $43.07B 2.43 $7.54B $3.20 16.14

Question 25

Do insiders and institutionals hold more shares of TEVA or GSK?

Accepted Answer

54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Question 26

Is TEVA or GSK more profitable?

Accepted Answer

GSK has a net margin of 14.56% compared to Teva Pharmaceutical Industries' net margin of 4.08%. GSK's return on equity of 43.23% beat Teva Pharmaceutical Industries' return on equity. Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries 4.08% 32.64% 6.34% GSK 14.56% 43.23% 11.60%

Question 27

Which has more risk and volatility, TEVA or GSK?

Accepted Answer

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Question 28

Does the media refer more to TEVA or GSK?

Accepted Answer

In the previous week, Teva Pharmaceutical Industries had 3 more articles in the media than GSK. MarketBeat recorded 8 mentions for Teva Pharmaceutical Industries and 5 mentions for GSK. Teva Pharmaceutical Industries' average media sentiment score of 0.65 beat GSK's score of 0.56 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Question 29

Do analysts prefer TAK or TEVA?

Accepted Answer

Teva Pharmaceutical Industries has a consensus price target of $42.22, suggesting a potential upside of 13.49%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90

Question 30

Is TAK or TEVA a better dividend stock?

Accepted Answer

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 2.7%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Teva Pharmaceutical Industries pays out 168.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Question 31

Which has stronger earnings & valuation, TAK or TEVA?

Accepted Answer

Teva Pharmaceutical Industries has lower revenue, but higher earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Takeda Pharmaceutical $28.32B 2.06 -$1.01B $0.34 53.63 Teva Pharmaceutical Industries $17.31B 2.50 $1.41B $0.60 62.01

Question 32

Do insiders & institutionals believe in TAK or TEVA?

Accepted Answer

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Question 33

Is TAK or TEVA more profitable?

Accepted Answer

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Takeda Pharmaceutical's net margin of 3.80%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Takeda Pharmaceutical's return on equity. Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical 3.80% 10.95% 5.34% Teva Pharmaceutical Industries 4.08% 32.64% 6.34%

Question 34

Which has more risk and volatility, TAK or TEVA?

Accepted Answer

Takeda Pharmaceutical has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Question 35

Does the media refer more to TAK or TEVA?

Accepted Answer

In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 9 mentions for Takeda Pharmaceutical and 8 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.65 beat Takeda Pharmaceutical's score of 0.59 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Metric	Teva Pharmaceutical Industries	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$43.34B	$12.49B	$7.31B	$24.27B
Dividend Yield	N/A	2.61%	2.53%	3.69%
P/E Ratio	61.99	780.58	272.35	30.23
Price / Sales	2.50	761.20	623.76	20.41
Price / Cash	9.90	98.02	78.57	32.63
Price / Book	5.59	12.00	13.14	7.70
Net Income	$1.41B	$2.82B	$3.47B	$1.07B
7 Day Performance	-0.79%	2.59%	1.23%	-0.19%
1 Month Performance	20.85%	6.35%	8.51%	2.88%
1 Year Performance	104.69%	7.70%	25.60%	14.59%

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TEVA Teva Pharmaceutical Industries	3.3854 of 5 stars	$37.20 -2.4%	$42.22 +13.5%	+109.6%	$43.34B	$17.31B	61.99	33,950
PFE Pfizer	3.9848 of 5 stars	$26.88 +0.3%	$28.28 +5.2%	+13.4%	$152.69B	$62.58B	35.37	75,000
BMY Bristol Myers Squibb	4.6896 of 5 stars	$64.71 +1.4%	$66.06 +2.1%	+43.9%	$130.39B	$48.19B	14.25	32,500	Positive News
SNY Sanofi	3.6487 of 5 stars	$44.41 +1.6%	$49.50 +11.5%	-8.2%	$106.00B	$49.35B	23.25	74,846	Positive News
GSK GSK	2.7149 of 5 stars	$50.29 +1.6%	$53.00 +5.4%	+31.4%	$100.16B	$43.07B	15.73	66,841	Dividend Cut Analyst Forecast

Teva Pharmaceutical Industries (TEVA) Competitors

TEVA vs. PFE, BMY, SNY, GSK, and TAK

How does Teva Pharmaceutical Industries compare to Pfizer?

Summary

How does Teva Pharmaceutical Industries compare to Bristol Myers Squibb?

Summary

How does Teva Pharmaceutical Industries compare to Sanofi?

Summary

How does Teva Pharmaceutical Industries compare to GSK?

Summary

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA vs. The Competition

Teva Pharmaceutical Industries Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Teva Pharmaceutical Industries (TEVA) Competitors

TEVA vs. PFE, BMY, SNY, GSK, and TAK

How does Teva Pharmaceutical Industries compare to Pfizer?

Which has preferable valuation and earnings, PFE or TEVA?

Is PFE or TEVA a better dividend stock?

Does the media prefer PFE or TEVA?

Which has more risk and volatility, PFE or TEVA?

Do analysts recommend PFE or TEVA?

Do institutionals and insiders hold more shares of PFE or TEVA?

Is PFE or TEVA more profitable?

Summary

How does Teva Pharmaceutical Industries compare to Bristol Myers Squibb?

Do analysts rate TEVA or BMY?

Does the media prefer TEVA or BMY?

Do insiders & institutionals believe in TEVA or BMY?

Which has better earnings & valuation, TEVA or BMY?

Which has more volatility & risk, TEVA or BMY?

Is TEVA or BMY a better dividend stock?

Is TEVA or BMY more profitable?

Summary

How does Teva Pharmaceutical Industries compare to Sanofi?

Does the media favor TEVA or SNY?

Which has more volatility & risk, TEVA or SNY?

Do analysts rate TEVA or SNY?

Which has preferable earnings and valuation, TEVA or SNY?

Is TEVA or SNY a better dividend stock?

Do insiders and institutionals believe in TEVA or SNY?

Is TEVA or SNY more profitable?

Summary

How does Teva Pharmaceutical Industries compare to GSK?

Is TEVA or GSK a better dividend stock?

Do analysts recommend TEVA or GSK?

Do insiders and institutionals hold more shares of TEVA or GSK?

Does the media refer more to TEVA or GSK?

Is TEVA or GSK more profitable?

Which has more risk and volatility, TEVA or GSK?

Which has better earnings & valuation, TEVA or GSK?

Summary

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Does the media refer more to TAK or TEVA?

Which has more risk and volatility, TAK or TEVA?

Is TAK or TEVA a better dividend stock?

Which has stronger earnings & valuation, TAK or TEVA?

Is TAK or TEVA more profitable?

Do analysts prefer TAK or TEVA?

Do insiders & institutionals believe in TAK or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA vs. The Competition

Teva Pharmaceutical Industries Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools